Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
11.56
+0.04 (0.35%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Nurix Therapeutics Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for Nurix Therapeutics stock have an average target of 30.71, with a low estimate of 16 and a high estimate of 41. The average target predicts an increase of 165.66% from the current stock price of 11.56.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nurix Therapeutics stock from 17 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 7 | 7 | 7 |
| Buy | 8 | 9 | 9 | 9 | 8 | 8 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 17 | 17 | 17 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $32 → $25 | Buy | Maintains | $32 → $25 | +116.26% | Apr 9, 2025 |
| Stifel | Stifel | Strong Buy Maintains $36 → $35 | Strong Buy | Maintains | $36 → $35 | +202.77% | Apr 9, 2025 |
| Needham | Needham | Strong Buy Maintains $28 → $27 | Strong Buy | Maintains | $28 → $27 | +133.56% | Apr 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +211.42% | Apr 2, 2025 |
| Leerink Partners | Leerink Partners | Hold Initiates $16 | Hold | Initiates | $16 | +38.41% | Mar 17, 2025 |
Financial Forecast
Revenue This Year
61.55M
from 54.55M
Increased by 12.84%
Revenue Next Year
57.95M
from 61.55M
Decreased by -5.86%
EPS This Year
-3.09
from -2.88
EPS Next Year
-3.32
from -3.09
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 93.7M | 99.8M | 214.5M | ||
| Avg | 61.6M | 57.9M | 87.2M | ||
| Low | 18.1M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 71.8% | 62.1% | 270.2% | ||
| Avg | 12.8% | -5.9% | 50.4% | ||
| Low | -66.8% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.14 | -1.70 | -1.63 | ||
| Avg | -3.09 | -3.32 | -3.15 | ||
| Low | -3.49 | -4.51 | -4.07 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.